Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
As various governments are enhancing the focus on treating rare diseases, the demand for hunter syndrome treatment is rising. The commercialisation of innovative hunter syndrome treatments and therapies is also propelling the market growth. With the initiation of clinical trials to determine the effectiveness of new treatments for hunter syndrome, the market is poised to witness robust growth. In addition, stem cell-based gene therapy is increasingly investigated to treat children with hunter syndrome, which is likely to fuel the market’s expansion. The increasing research activities to develop new therapies that are designed to deliver proteins to peripheral tissues and the brain for treating somatic symptoms as well as neuronopathic features of hunter syndrome are expected to augment the market growth in the forecast period.
REGENXBIO Inc. (NASDAQ: RGNX), one of the leading companies in the market, announced in February 2022 the additional positive interim data from Cohort 1-3 of the ongoing Phase I/II trial of RGX-121. RGX-121 is an investigational one-time gene therapy that is designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. It is being investigated for the treatment of patients up to 5 years old that are diagnosed with Hunter Syndrome, also known as Mucopolysaccharidosis Type II (MPS II). The company announced that the interim data demonstrates neurodevelopmental trajectories in patients from Cohorts 1 and 2 and dose-dependent reductions in CSF biomarkers across cohorts. Moreover, the data support the early positive signals that are witnessed in the emerging clinical profile of RGX-121 for hunter syndrome treatment.
Market Analysis by Treatment Type, Complication, Route of Administration, End Use, Distribution Channel, and Region:
Key Findings of the Report:
Key Offerings of the Report:
The major players in the global hunter syndrome treatment market are Denali Therapeutics Inc., ArmaGen, Inc., Sangamo Therapeutics Inc., CANbridge Life Sciences Ltd. and REGENXBIO Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.